February 20, 2017
Mereo BioPharma’s rare bone disease drug to develop sooner
Mereo BioPharma’s bone disease drug BPS-804 has been accepted to participate in the European Medicines Agency’s (EMA) Adaptive Pathways programme.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
February 20, 2017
TerSera buys commercial rights for AstraZeneca’s cancer drug in North America
AstraZeneca has entered into an agreement with TerSera Therapeutics for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada, an injectable luteinising hormone-releasing hormone agonist, used to treat prostate cancer, breast cancer and certain benign gynaecological disorders.
February 17, 2017
Risperdal gynecomastia lawsuits move forward, as Pennsylvania mass tort program schedules March meeting
Risperdal lawsuits involving Johnson & Johnson medication to gynecomastia, (male breast growth) and other side effects allegedly associated with use of the atypical antipsychotic medication continue to move forward in the Philadelphia Court of Common Pleas, said Bernstein Liebhard LLP is a New York-based law firm representing the victims of defective drugs and medical devices in USA.
February 17, 2017
Vote of confidence for life-science sector, Arix rasies £100M in initial public offering
London-listed healthcare company Arix Bioscience said on Friday it raised £100 million in its Initial Public Offering, with total market capitalisation at Admission to be £187 million.
February 17, 2017
Abbvie okays $5 billion to boost its stock repurchase program
AbbVie plans to it increase its earnings per share and elevates the market value of the remaining shares, as it has authorized a $5 billion increase to AbbVie’s existing stock repurchase program.
February 17, 2017
Janssen’s tests prostate cancer drug Zytiga in real-world
Jansen revealed results from its real-world study of its cancer drug Zytiga in combination with Prednisone, to treat men with prostate cancer.
February 17, 2017
AstraZeneca’s breast cancer drug trial shows positive results
AstraZeneca has announced positive results from its Phase III OLYMPIAD trial comparing Lynparza (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations.
February 17, 2017
Takeda, TiGenix’s orphan drug test meets endpoint
Takeda and TiGenix have presented new data from the Phase 3 ADMIRE-CD clinical trial of treatment refractory complex perianal fistulas in patients with Crohn’s disease at the 12th Congress of the European Crohn’s and Colitis Organisation (ECCO).
February 17, 2017
AbbVie declares quarterly dividend
AbbVie, the global research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories has declared a quarterly cash dividend of $0.64 per share.
February 16, 2017
Stada confirms another bidder
On Thursday, STADA Arzneimittel AG confirmed that it has received another legally non-binding conditional expression of interest regarding a bid for the acquisition of up to 100 percent of the shares in the company at an indicative takeover price of €58.00 per share.